Stellular Bio has raised early-stage investment to advance its treatment candidate, STLR-201, into clinical testing as a potential off-the-shelf therapeutic option for dry eye caused by Sjögren’s disease. Part of a therapy class called platelet-derived regenerative biologics (PRBs), STLR-201 is derived from stem cells that can produce platelets,…
A new publicly available artificial intelligence (AI) tool that analyzes results from routine laboratory blood tests may improve the diagnosis of Sjögren’s disease, according to a multicenter study in China. The AI system, called Sjogren Multi-criterion Feature Integration Framework (SMFIF), distinguished people with Sjögren’s from those with Sjögren’s-like…
Ianalumab, an experimental treatment for Sjögren’s disease from Novartis, has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA). The FDA gives this designation to experimental therapies that have the potential to address unmet needs in the care of serious diseases, with the goal…
Primary Sjögren’s disease may be divided into two main clinical subtypes, according to a recent study that used artificial intelligence. “Our study suggests that primary Sjögren’s syndrome consists of distinct clinical subtypes with different organ involvement patterns and immunological features,” the researchers wrote. “The data-driven classification system complements traditional…
Get regular updates to your inbox.
